Blueprint to Address Patent Thickets, Improve Competition, and Lower Prescription Drug Prices
PTO Pick Kathi Vidal Must Incorporate an Equity Agenda
I-MAK’s response to the senseless killings of Black people with impunity
Report Finds 89% of Total U.S. Patent Applications on Humira Were Filed After FDA Approval – Pointing to a Deliberate Strategy to Delay Competition
I-MAK Welcomes Two New Board Members to Champion the Access to Medicines Movement
China Patent Challenge Compels Gilead to Withdraw Key Patent Claims on Sofosbuvir Base Compound, Opening Life-Saving Hepatitis C Treatment Access for Millions
Report: Hundreds of Patents on America’s Top Selling Drugs are Triggering Price Hikes and Blocking Competition
I-MAK & Patients for Affordable Drugs File Amicus Brief with the US Supreme Court in support of RPX Corp in RPX Corp. v. Chanbond LLC
I-MAK & Delhi Network of Positive People File Opposition to Prevent AbbVie Patent Grant on Hepatitis C Treatment
Major Win for Patients as Brazil Rejects a Key Patent on Gilead Hepatitis C Drug and European Court of Justice Opinion Denies Patent Extension to Gilead’s HIV Drug